219 related articles for article (PubMed ID: 1578205)
1. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening: a decision analysis.
Cantor SB; Spann SJ; Volk RJ; Cardenas MP; Warren MM
J Fam Pract; 1995 Jul; 41(1):33-41. PubMed ID: 7798064
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
4. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
5. Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores.
Naughton CK; Miller DC; Yan Y
J Urol; 2001 Jan; 165(1):100-3. PubMed ID: 11125374
[TBL] [Abstract][Full Text] [Related]
6. Minority issues in prostate disease.
French DB; Jones LA
Med Clin North Am; 2005 Jul; 89(4):805-16. PubMed ID: 15925651
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer. When to offer screening in the primary care setting.
Gambert SR
Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
[TBL] [Abstract][Full Text] [Related]
8. Predictors of utilities for health states in early stage prostate cancer.
Saigal CS; Gornbein J; Nease R; Litwin MS
J Urol; 2001 Sep; 166(3):942-6. PubMed ID: 11490251
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
10. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
11. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
12. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
[TBL] [Abstract][Full Text] [Related]
13. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
[TBL] [Abstract][Full Text] [Related]
14. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
15. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening.
Downer MC; Jullien JA; Speight PM
Community Dent Health; 1997 Dec; 14(4):227-32. PubMed ID: 9458580
[TBL] [Abstract][Full Text] [Related]
16. [Detection of cancer of the prostate. A study of 600 cases].
Teillac P; Bron J; Tobolski F; Cussenot O; Lesourd A; Leroy M; Toubert ME; Brocheriou C; Laval-Jeantet M; Le Duc A
Ann Urol (Paris); 1990; 24(1):37-41. PubMed ID: 1690963
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer Tx. Therapeutic options based on tumor grade, life expectancy, and patient preferences.
Cohen SP; Jaskulsky SR
Geriatrics; 2001 Feb; 56(2):39, 42, 47-8 passim. PubMed ID: 11219024
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
20. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
